KPC Pharmaceuticals,Inc. (SHA:600422)
15.38
+0.02 (0.13%)
Apr 30, 2025, 2:45 PM CST
KPC Pharmaceuticals,Inc. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jan '21 Jan 1, 2021 | 2015 - 2019 |
Operating Revenue | 7,960 | 8,266 | 7,720 | 8,045 | 7,606 | Upgrade
|
Other Revenue | 441.93 | 163.98 | 562.24 | 208.77 | 110.76 | Upgrade
|
Revenue | 8,401 | 8,430 | 8,282 | 8,254 | 7,717 | Upgrade
|
Revenue Growth (YoY) | -0.34% | 1.79% | 0.35% | 6.95% | -4.96% | Upgrade
|
Cost of Revenue | 4,771 | 4,544 | 4,855 | 4,865 | 4,409 | Upgrade
|
Gross Profit | 3,631 | 3,886 | 3,427 | 3,389 | 3,308 | Upgrade
|
Selling, General & Admin | 2,597 | 2,983 | 2,812 | 2,779 | 2,665 | Upgrade
|
Research & Development | 106.76 | 94.2 | 69.65 | 100.52 | 128.45 | Upgrade
|
Other Operating Expenses | 81.5 | 84.64 | -57.25 | 64.56 | -7.63 | Upgrade
|
Operating Expenses | 2,831 | 3,206 | 2,864 | 2,980 | 2,793 | Upgrade
|
Operating Income | 800.18 | 679.83 | 563.54 | 409.19 | 515.53 | Upgrade
|
Interest Expense | -26.36 | -21.61 | -40.73 | -33.59 | -29.16 | Upgrade
|
Interest & Investment Income | 27.78 | 38.14 | 12.05 | 156.1 | 23.43 | Upgrade
|
Currency Exchange Gain (Loss) | 1.92 | 2.08 | 3.08 | -3.48 | -6.38 | Upgrade
|
Other Non Operating Income (Expenses) | 13.16 | 7.55 | -27.97 | -7.25 | -12.36 | Upgrade
|
EBT Excluding Unusual Items | 816.67 | 705.99 | 509.97 | 520.97 | 491.06 | Upgrade
|
Gain (Loss) on Sale of Investments | 6.92 | 1.03 | 10.67 | -0.96 | -1.36 | Upgrade
|
Gain (Loss) on Sale of Assets | 1.01 | 1.04 | 15.21 | 2.2 | 51.29 | Upgrade
|
Asset Writedown | -2.04 | -30.12 | -57.73 | -0.29 | -0.36 | Upgrade
|
Other Unusual Items | 112.01 | 108.45 | -0.84 | 109.37 | -0.14 | Upgrade
|
Pretax Income | 934.57 | 786.38 | 477.29 | 631.29 | 540.49 | Upgrade
|
Income Tax Expense | 183.35 | 143.7 | 91.83 | 118.07 | 78.3 | Upgrade
|
Earnings From Continuing Operations | 751.22 | 642.67 | 385.46 | 513.21 | 462.18 | Upgrade
|
Minority Interest in Earnings | -103.14 | -101.96 | -2.28 | -5.55 | -5.33 | Upgrade
|
Net Income | 648.08 | 540.71 | 383.18 | 507.67 | 456.86 | Upgrade
|
Net Income to Common | 648.08 | 540.71 | 383.18 | 507.67 | 456.86 | Upgrade
|
Net Income Growth | 19.86% | 41.11% | -24.52% | 11.12% | 0.56% | Upgrade
|
Shares Outstanding (Basic) | 754 | 762 | 751 | 758 | 759 | Upgrade
|
Shares Outstanding (Diluted) | 754 | 762 | 751 | 758 | 759 | Upgrade
|
Shares Change (YoY) | -1.05% | 1.36% | -0.84% | -0.19% | -0.33% | Upgrade
|
EPS (Basic) | 0.86 | 0.71 | 0.51 | 0.67 | 0.60 | Upgrade
|
EPS (Diluted) | 0.86 | 0.71 | 0.51 | 0.67 | 0.60 | Upgrade
|
EPS Growth | 21.13% | 39.22% | -23.88% | 11.33% | 0.89% | Upgrade
|
Free Cash Flow | 728.63 | 644.69 | 152.15 | 15.46 | 251.21 | Upgrade
|
Free Cash Flow Per Share | 0.97 | 0.85 | 0.20 | 0.02 | 0.33 | Upgrade
|
Dividend Per Share | 0.300 | 0.200 | 0.160 | 0.270 | 0.230 | Upgrade
|
Dividend Growth | 50.00% | 25.00% | -40.74% | 17.39% | 15.00% | Upgrade
|
Gross Margin | 43.22% | 46.10% | 41.38% | 41.06% | 42.87% | Upgrade
|
Operating Margin | 9.52% | 8.06% | 6.80% | 4.96% | 6.68% | Upgrade
|
Profit Margin | 7.71% | 6.41% | 4.63% | 6.15% | 5.92% | Upgrade
|
Free Cash Flow Margin | 8.67% | 7.65% | 1.84% | 0.19% | 3.26% | Upgrade
|
EBITDA | 964.84 | 855.23 | 744.03 | 568.04 | 666.42 | Upgrade
|
EBITDA Margin | 11.48% | 10.14% | 8.98% | 6.88% | 8.64% | Upgrade
|
D&A For EBITDA | 164.66 | 175.4 | 180.49 | 158.86 | 150.89 | Upgrade
|
EBIT | 800.18 | 679.83 | 563.54 | 409.19 | 515.53 | Upgrade
|
EBIT Margin | 9.52% | 8.06% | 6.80% | 4.96% | 6.68% | Upgrade
|
Effective Tax Rate | 19.62% | 18.27% | 19.24% | 18.70% | 14.49% | Upgrade
|
Revenue as Reported | 8,401 | 8,430 | 8,282 | 8,254 | 7,717 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.